Opin vísindi

Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes

Show simple item record

dc.contributor.author Schmidt, Signe
dc.contributor.author Frandsen, Christian S.
dc.contributor.author Dejgaard, Thomas F.
dc.contributor.author Vistisen, Dorte
dc.contributor.author Halldórsson, Þórhallur Ingi
dc.contributor.author Olsen, Sjudur F.
dc.contributor.author Jensen, Jens Erik B.
dc.contributor.author Madsbad, Sten
dc.contributor.author Andersen, Henrik U.
dc.contributor.author Nørgaard, Kirsten
dc.date.accessioned 2022-01-11T01:02:28Z
dc.date.available 2022-01-11T01:02:28Z
dc.date.issued 2021-09-30
dc.identifier.citation Schmidt , S , Frandsen , C S , Dejgaard , T F , Vistisen , D , Halldórsson , Þ I , Olsen , S F , Jensen , J E B , Madsbad , S , Andersen , H U & Nørgaard , K 2021 , ' Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes ' , Diabetes, Obesity and Metabolism . https://doi.org/10.1111/dom.14567
dc.identifier.issn 1462-8902
dc.identifier.other PURE: 41714576
dc.identifier.other PURE UUID: a630a67d-0030-4c68-9750-74c8fb3e14ab
dc.identifier.other Scopus: 85117111091
dc.identifier.other unpaywall: 10.1111/dom.14567
dc.identifier.uri https://hdl.handle.net/20.500.11815/2810
dc.description Funding Information: We thank the participants and research team members Anette Hougaard and Merete Meldgaard Andersen for making this study possible. This study was supported by an unrestricted grant from Novo Nordisk A/S. The funder had no role in any part of this article. Funding Information: S.S. has served on an advisory panel for Medtronic and has received a research fellowship grant from the Danish Diabetes Academy supported by the Novo Nordisk Foundation. C.S.F. has received research support and lecture fees from Novo Nordisk. T.F.D. has served on advisory panels for Novo Nordisk, has received research support from Novo Nordisk and AstraZeneca and has received lecture fees from Novo Nordisk, AstraZeneca, Sanofi‐Aventis and Boehringer‐Ingelheim. D.V. is a shareholder in Novo Nordisk. J‐E.B.J. has served on advisory panels for Amgen, Eli Lilly, UCB Pharma, and Gedeon Richter, and has received lecture fees from Amgen, Eli Lilly, UCB Pharma, Gilead and Otsuka. S.M. has served on advisory panels for AstraZeneca, Boehringer‐Ingelheim, Eli Lilly, Merck Sharp & Dome, Novo Nordisk, Sanofi and Bayer, has received lecture fees from AstraZeneca, Boehringer‐Ingelheim, Merck Sharp & Dohme, Novo Nordisk and Sanofi, and has received research grants from Novo Nordisk and Boehringer‐Ingelheim. H.U.A. is a shareholder in Novo Nordisk, has served on advisory panels for Abbott, Novo Nordisk and AstraZeneca, and has received lecture fees from Nordic Infucare. K.N. is a shareholder in Novo Nordisk, has received research support from Novo Nordisk, Roche Diagnostics, Medtronic and Zealand Pharma, has received lecture fees from Medtronic, Roche Diagnostics, Rubin Medical, Sanofi, Zealand Pharma, Novo Nordisk and Dexcom, and has served on advisory panels for Medtronic, Abbott and Novo Nordisk. T.H. and S.F.O. have nothing to declare. Publisher Copyright: © 2021 John Wiley & Sons Ltd.
dc.description.abstract Aims: To present secondary outcome analyses of liraglutide treatment in overweight adults with insulin pump-treated type 1 diabetes (T1D), focusing on changes in body composition and dimensions, and to evaluate changes in food intake to identify potential dietary drivers of liraglutide-associated weight loss. Materials and methods: A 26-week randomized placebo-controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump-treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)- and body weight-reducing effects. For secondary outcome analysis, dual X-ray absorptiometry scans were completed at Weeks 0 and 26, and questionnaire-based food frequency recordings were obtained at Weeks 0, 13 and 26 to characterize liraglutide-induced changes in body composition and food intake. Results: Total fat and lean body mass decreased in liraglutide-treated participants (fat mass −4.6 kg [95% confidence interval {CI} −5.7; −3.5], P < 0.001; lean mass −2.5 kg [95% CI −3.2;-1.7], P < 0.001), but remained stable in placebo-treated participants (fat mass −0.3 kg [95% CI −1.3;0.8], P = 0.604; lean mass 0.0 kg [95% CI −0.7;0.7]; P = 0.965 [between-group P values <0.001]). Participants reduced their energy intake numerically more in the liraglutide arm (−1.1 MJ [95% CI −2.0;-0.02], P = 0.02) than in the placebo arm (−0.9 MJ [95% CI −2.0;0.1], P = 0.22), but the between-group difference was statistically insignificant (P = 0.42). However, energy derived from added sugars decreased by 27% in the liraglutide arm compared with an increase of 14% in the placebo arm (P = 0.004). Conclusions: Liraglutide lowered fat and lean body mass compared with placebo. Further, liraglutide reduced intake of added sugars. However, no significant difference in total daily energy intake was detected between liraglutide- and placebo-treated participants.
dc.format.extent
dc.language.iso en
dc.relation.ispartofseries Diabetes, Obesity and Metabolism; ()
dc.rights info:eu-repo/semantics/openAccess
dc.subject Efnaskipti
dc.subject Liraglútíð
dc.subject Liraglútíð
dc.subject Mataræði
dc.subject Sykursýki
dc.subject Líkamsþyngd
dc.subject body composition
dc.subject food frequency
dc.subject insulin pump therapy
dc.subject liraglutide
dc.subject type 1 diabetes
dc.subject weight loss
dc.subject Internal Medicine
dc.subject Endocrinology, Diabetes and Metabolism
dc.subject Endocrinology
dc.title Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi https://doi.org/10.1111/dom.14567
dc.relation.url http://www.scopus.com/inward/record.url?scp=85117111091&partnerID=8YFLogxK
dc.contributor.department Faculty of Food Science and Nutrition


Files in this item

This item appears in the following Collection(s)

Show simple item record